Цель исследования

tiblj

Туберкулез и болезни легких

Tuberculosis and Lung Diseases

2075-12302542-1506

Медицинские знания и технологии

10.58838/2075-1230-2025-103-2-26-37

tiblj-1877

Research Article

ОРИГИНАЛЬНЫЕ СТАТЬИ

ORIGINAL ARTICLES

Эффективность и безопасность коротких режимов химиотерапии лекарственно-устойчивого туберкулеза: обзор литературы и метаанализ

Effectiveness and Safety of Short-Course Chemotherapy Regimens for Drug-Resistant Tuberculosis: Literature Review and Meta-Analysis

https://orcid.org/0000-0002-9621-9271

Абрамченко

А. В.

Abramchenko

A. V.

Абрамченко Анна Валентиновна - Научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций, ассистент кафедры фтизиатрии ИКМ ФГАОУ ВО «РНИМУ им. Н.И. Пирогова» МЗ РФ

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Anna V. Abramchenko - Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections, Assistant of Phthisiology Department, Pirogov Russian National Research Medical University

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

av.abramchenko@mail.ru

https://orcid.org/0000-0002-4132-0049

Романова

М. И.

Romanova

M. I.

Романова Мария Игоревна - Младший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Maria I. Romanova - Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

RomanovaMI@nmrc.ru

https://orcid.org/0000-0002-3138-6538

Гайда

А. И.

Gayda

A. I.

Гайда Анастасия Игоревна - К. м. н., старший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Anastasiya I. Gayda - Candidate of Medical Sciences, Senior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

nsovca@yandex.ru

https://orcid.org/0000-0002-5396-7552

Можокина

Г. Н.

Mozhokina

G. N.

Можокина Галина Николаевна - Д. м. н., ведущий научный сотрудник лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Galina N. Mozhokina - Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

mojokina@mail.ru

https://orcid.org/0000-0001-6596-9777

Самойлова

А. Г.

Samoylova

A. G.

Самойлова Анастасия Геннадьевна - Д. м. н., заместитель директора по науке

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Anastasiya G. Samoylova -Doctor of Medical Sciences, Deputy Director for Research

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

a.samoilova.nmrc@mail.ru

https://orcid.org/0000-0002-0637-7955

Васильева

И. А.

Vasilyeva

I. A.

Васильева Ирина Анатольевна - Д. м. н, профессор, директор, заведующая кафедрой фтизиатрии ИКМ ФГАОУ ВО «РНИМУ им. Н. И. Пирогова» МЗ РФ

127473, Москва, ул. Достоевского, д. 4, к. 2

Тел.+7 (495) 631-15-15

Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director, Head of Phthisiology Department, Pirogov Russian National Research Medical University

4 Build. 2 Dostoevsky St., Moscow, 127473

Phone:+7 (495) 631-15-15

vasil39@list.ru

ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; Pirogov Russian National Research Medical University, Russian Ministry of HealthRussian Federation

ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian Federation

2025

27042025

10322637

2025

Абрамченко А.В., Романова М.И., Гайда А.И., Можокина Г.Н., Самойлова А.Г., Васильева И.А.

Abramchenko A.V., Romanova M.I., Gayda A.I., Mozhokina G.N., Samoylova A.G., Vasilyeva I.A.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.tibl-journal.com/jour/article/view/1877

Цель исследования

Цель исследования: на основе систематического и метааналитического исследования оценить клиническую эффективность и безопасность коротких режимов химиотерапии у больных с лекарственно-устойчивым туберкулезом.

Материалы и методы

Материалы и методы. Систематический поиск научной литературы был проведен в электронных библиотеках PubMed и eLibrary, опубликованных за период с 01.01.2018 по 01.10.2023 гг. По ключевым словам «лечение туберкулеза с лекарственной устойчивостью возбудителя, рандомизированные клинические исследования» было выбрано 66 исследований. При выполнении ручного просмотра были определены 7 публикаций с требуемыми для метаанализа параметрами.

Результаты

Результаты. Проведенный одногрупповой метаанализ по оценке эффективности краткосрочных схем химиотерапии показал: благоприятный исход может быть достигнут в 80,9% случаев; неблагоприятный исход наступает в 19,4%; конверсия культуры мокроты к 8 неделям ХТ имеет место в 74,6% случаев; СНЯ зарегистрированы у 15,1% пациентов, НЯ 3 степени и выше – у 39,5% (на основании 4 публикаций).

The objective

The objective: to evaluate clinical effectiveness and safety of short-course chemotherapy regimens in patients with drug-resistant tuberculosis based on a systematic and meta-analytic study.

Subjects and Methods

Subjects and Methods. A systematic search for scientific publications published between 01.01.2018 and 01.10.2023 was conducted in PubMed and eLibrary. Sixty-six studies were selected using the keywords “treatment of drug-resistant tuberculosis, randomized clinical trials”. By a manual review, 7 publications meeting required parameters for meta-analysis were identified.

Results

Results. A single-group meta-analysis of the effectiveness of short-term chemotherapy regimens demonstrated the following: a favorable outcome can be achieved in 80.9% of cases; an unfavorable outcome occurs in 19.4%; sputum culture conversion by 8 weeks of chemotherapy is achieved in 74.6% of cases; SAEs were registered in 15.1% of patients, grade 3 and higher SAEs- in 39.5% (based on 4 publications).

лекарственно-устойчивый туберкулезкороткие режимы химиотерапииметаанализэффективностьбезопасность

drug-resistant tuberculosisshort chemotherapy regimensmeta-analysiseffectivenesssafety

References1

Марьяндышев А.О., Кулижская А.И., Химова Е.С., Перхин Д.В., Свешникова О.М., Преснова С.Э., Курочкина Н.П., Сотников А.С., Лещева Н.А., Васильева И.А. Использование укороченных схем лечения туберкулеза с множественной лекарственной устойчивостью в Архангельской, Мурманской, Белгородской областях // Туберкулез и болезни легких. – 2019. – Т. 97, № 7. – С. 5-10. https://doi.org/10.21292/2075-1230-2019-97-7-5-10

Maryandyshev A.O., Kulizhskaya A.I., Khimova E.S., Perkhin D.V., Sveshnikova O.M., Presnova S.E., Kurochkina N.P., Sotnikov A.S., Lescheva N.A., Vasilyeva I.A. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod Regions. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 7, pp. 5-10. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-7-5-10

Bhering M., Kritski A., Nunes C., Duarte R. Multidrug-resistant tuberculosis in Lisbon: unfavourable treatment and associated factors, 2000–2014 // The International Journal of Tuberculosis and Lung Disease. – 2019. – Vol. 23, № 10. – Р. 1075–1081. https://doi.org/10.5588/ijtld.18.0596

Bhering M., Kritski A., Nunes C., Duarte R. Multidrug-resistant tuberculosis in Lisbon: unfavourable treatment and associated factors, 2000–2014. The International Journal Tuberculosis and Lung Diseases, 2019, vol. 23, no. 10, pp. 1075-1081. https://doi.org/10.5588/ijtld.18.0596

Bull World Health Organ. – 2014. – Vol. 92, № 1-6. Available at: https://docs.yandex.ru/docs/view?tm=1744394614&tld=ru&lang=ru&name=byulleten%27_voz_vypusk_92_nomera1_62014.rus.pdf&text=Bull%20World%20Health%20Organ%202014%3B%2092%3A68%E2%80%9374&url=https%3A%2F%2F [Ассessed 12 Dec 2024].

Bull World Health Organ., 2014, vol. 92, no. 1-6. Available: https://docs.yandex.ru/docs/view?tm=1744394614&tld=ru&lang=ru&name=byulleten%27_voz_vypusk_92_nomera1_62014.rus.pdf&text=Bull%20World%20Health%20Organ%202014%3B%2092%3A68%E2%80%9374&url=https%3A%2F%2F Ассessed December 12, 2024

Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Publish Date: November 27, 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [Ассessed 12 Dec 2024].

Common Terminology Criteria for Adverse Events (CTCAE), v5.0 Publish Date: November 27, 2017. Available: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf Ассessed December 12, 2024

Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R., McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M. Bedaquiline-Pretomanid-Linezo lid Regimens for Drug-Resistant Tuberculosis // N Engl J Med. – 2022. – № 387. – P. 810-823.

Conradie F., Bagdasaryan T.R., Borisov S., Howell P., Mikiashvili L., Ngubane N., Samoilova A., Skornykova S., Tudor E., Variava E., Yablonskiy P., Everitt D., Wills G.H., Sun E., Olugbosi M., Egizi E., Li M., Holsta A., Timm J., Bateson A., Crook A.M., Fabiane S.M., Hunt R., McHugh T.D., Tweed C.D., Foraida S., Mendel C.M., Spigelman M. Bedaquiline-pretomanid-linezoli d regimens for drug-resistant tuberculosis. N. Engl. J. Med., 2022, no. 387, pp. 810-823.

Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel C.M., Egizi E., Moreira J., Timm J., McHugh T.D., Wills G.H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis // N Engl J Med. – 2020. – № 382. – P. 893-902.

Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel C.M., Egizi E., Moreira J., Timm J., McHugh T.D., Wills G.H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2020, no. 382, pp. 893-902.

Du Y., Qiu C., Chen X., Wang J., Jing W., Pan H., Chen W., Liu Y., Li C., Xi X., Yin H., Zeng J., Zhang X., Xu T., Wang Q., Guo R., Wang J., Pang Y., Chu N. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China // Clin Infect Dis. – 2020. – № 71. – P. 1047-1054.

Du Y., Qiu C., Chen X., Wang J., Jing W., Pan H., Chen W., Liu Y., Li C., Xi X., Yin H., Zeng J., Zhang X., Xu T., Wang Q., Guo R., Wang J., Pang Y., Chu N. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China. Clin. Infect. Dis., 2020, no. 71, pp. 1047-1054.

Esmail A., Oelofse S., Lombard C., Perumal R., Mbuthini L., Goolam Mahomed A., Variava E., Black J., Oluboyo P., Gwentshu N., Ngam E., Ackerman T., Marais L., Mottay L., Meier S., Pooran A., Tomasicchio M., Te Riele J., Derendinger B., Ndjeka N., Maartens G., Warren R., Martinson N., Dheda K. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study) // Am J Respir Crit Care Med. – 2022. – № 205. – P. 1214-1227.

Esmail A., Oelofse S., Lombard C., Perumal R., Mbuthini L., Goolam Mahomed A., Variava E., Black J., Oluboyo P., Gwentshu N., Ngam E., Ackerman T., Marais L., Mottay L., Meier S., Pooran A., Tomasicchio M., Te Riele J., Derendinger B., Ndjeka N., Maartens G., Warren R., Martinson N., Dheda K. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am. J. Respir. Crit. Care Med., 2022, no. 205, pp. 1214-1227.

Global Programme on Tuberculosis and Lung Health (GTB) 2023. Target regimen profiles for tuberculosis treatment, 2023 update. Geneva: World Health Organization; 2023. License: CC BY-NC-SA 3.0 IGO

Global Programme on Tuberculosis and Lung Health (GTB) 2023. Target regimen profiles for tuberculosis treatment, 2023 update. Geneva, World Health Organization, 2023. License: CC BY-NC-SA 3.0 IGO

Global tuberculosis report 2024. Geneva: World Health Organization; 2024. License: CC BY-NC-SA 3.0 IGO.

Global tuberculosis report 2024. Geneva, World Health Organization, 2024. License: CC BY-NC-SA 3.0 IGO.

Goodall R.L., Meredith S.K., Nunn A.J., Bayissa A., Bhatnagar A.K., Bronson G., Chiang C.Y., Conradie F., Gurumurthy M., Kirenga B., Kiria N., Meressa D., Moodliar R., Narendran G., Ngubane N., Rassool M., Sanders K., Solanki R., Squire S.B., Torrea G., Tsogt B., Tudor E., Van Deun A., Rusen I.D. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial // Lancet. – 2022. – № 400. – P. 1858-1868.

Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon // Int J Tuberc Lung Dis. – 2015. – № 19. – P. 517-524.

Kuaban C., Noeske J., Rieder H.L., Aït-Khaled N., Abena Foe J.L., Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tuberc. Lung Dis., 2015, no. 19, pp. 517-524.

Kyaw S.L. Loss to Follow-Up (LTFU) during Tuberculosis Treatment [http://doi.org/10.5772/intechopen.81900]. In: Healthcare Access –Regional Overviews [Working Title]. IntechOpen, 2019.

Kyaw S.L. Loss to follow-up (LTFU) during tuberculosis treatment. http://doi.org/10.5772/intechopen.81900. In: Healthcare Access–Regional Overviews [Working Title]. IntechOpen, 2019.

Mok J., Lee M., Kim D.K., Kim J.S., Jhun B.W., Jo K.W., Jeon D., Lee T., Lee J.Y., Park J.S., Lee S.H., Kang Y.A., Lee J.K., Kwak N., Ahn J.H., Shim T.S., Kim S.Y., Kim S., Kim K., Seok K.H., Yoon S., Kim Y.R., Kim J., Yim D., Hahn S., Cho S.N., Yim J.J. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea // Lancet. – 2022. – № 400. – P. 1522-1530.

Namukwaya E., Nakwagala F.N., Mulekya F., Mayanja-Kizza H., Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda // Afr Health Sci. – 2011. – № 11, Suppl 1. – Р. S105-111.

Namukwaya E., Nakwagala F.N., Mulekya F., Mayanja-Kizza H., Mugerwa R. Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. Afr. Health Sci., 2011, no. 11, suppl. 1, pp. S105-111.

Nunn A.J., Phillips P.P.J., Meredith S.K., Chiang C.Y., Conradie F., Dalai D., van Deun A., Dat P.T., Lan N., Master I., Mebrahtu T., Meressa D., Moodliar R., Ngubane N., Sanders K., Squire S.B., Torrea G., Tsogt B., Rusen I.D. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis // N Engl J Med. – 2019. – № 380. – P. 1201-1213.

Nunn A.J., Phillips P.P.J., Meredith S.K., Chiang C.Y., Conradie F., Dalai D., van Deun A., Dat P.T., Lan N., Master I., Mebrahtu T., Meressa D., Moodliar R., Ngubane N., Sanders K., Squire S.B., Torrea G., Tsogt B., Rusen I.D. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2019, no. 380, pp. 1201-1213.

Nyang'wa B.T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Solodovnikova V., Liverko I., Moodliar R., Dodd M., Ngubane N., Rassool M., McHugh T.D., Spigelman M., Moore D.A.J., Ritmeijer K., du Cros P., Fielding K. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis // N Engl J Med. – 2022. – № 387. – P. 2331-2343.

Nyang'wa B.T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Solodovnikova V., Liverko I., Moodliar R., Dodd M., Ngubane N., Rassool M., McHugh T.D., Spigelman M., Moore D.A.J., Ritmeijer K., du Cros P., Fielding K. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2022, no. 387, pp. 2331-2343.

Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses // Int J Tuberc Lung Dis. – 2014. – № 18. – P. 1188-1194.

Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int. J. Tuberc. Lung Dis., 2014, no. 18, pp. 1188-1194.

Prasad R., Singh A., Gupta N. Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis // Annals of the National Academy of Medical Sciences (India). – 2021. – № 57. – Р. 16-35. http://doi.org/10.1055/s-0040-1722535

Prasad R., Singh A., Gupta N. Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis. Annals of the National Academy of Medical Sciences (India), 2021, no. 57, pp. 16-35. http://doi.org/10.1055/s-0040-1722535

Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis // Am J Respir Crit Care Med. – 2010. – № 182. – P. 684-692.

Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med., 2010, no. 182, pp. 684-692.

WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022. License: CC BY-NC-SA 3.0IGO.

WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva, World Health Organization, 2022. License: CC BY-NC-SA 3.0IGO.

WHO, Key updates to the treatment of drug-resistant tuberculosis, June 2024.

World Health Organization. Global Tuberculosis Report; WHO / HTM / TB / 2012.6; WHO: Geneva, Switzerland, 2012.

World Health Organization. Global Tuberculosis Report; WHO/HTM/TB/2012.6; WHO, Geneva, Switzerland, 2012.

Yang Q., Han J., Shen J., Peng X., Zhou L., Yin X. Diagnosis and treatment of tuberculosis in adults with HIV // Medicine (Baltimore). – 2022. – Vol. 101, № 35. – Р. e30405. https://doi.org/10.1097/MD.0000000000030405

Yang Q., Han J., Shen J., Peng X., Zhou L., Yin X. Diagnosis and treatment of tuberculosis in adults with HIV. Medicine (Baltimore), 2022, vol. 101, no. 35, pp. e30405. https://doi.org/10.1097/MD.0000000000030405

The authors declare that there are no conflicts of interest present.